- any antithrombotic treatment including acetylsalicylic acid - active bacterial infection - active or in maintenance therapy neoplasm - inability to provide consent - any contraindication to the acetylsalicylic acid use - active peptic disease - active major pathological bleeding - recent (<30 days) major bleeding - recent intracranial bleeding - need to use therapeutic doses of oral anticoagulants or heparins - need to use combination antiplatelet drugs for clinical indication - hypersensitivity to acetylsalicylic acid or to any of the excipients - hypersensitivity to non-steroidal anti-inflammatory drugs (nsaids) - severe hepatic insufficiency (child-pugh class c). - severe heart failure (nyha class 3-4) - platelet count less than 150000 / mmc - haemostasis alteration (inr> 1.5, aptt> 1.5) - plasma fibrinogen <100 mg / dl - blood pressure >160/100 mmhg - concomitant treatment with serotonin reuptake inhibitors - participation in another pharmacological clinical trial

- any antithrombotic treatment including acetylsalicylic acid - active bacterial infection - active or in maintenance therapy neoplasm - inability to provide consent - any contraindication to the acetylsalicylic acid use - active peptic disease - active major pathological bleeding - recent (<30 days) major bleeding - recent intracranial bleeding - need to use therapeutic doses of oral anticoagulants or heparins - need to use combination antiplatelet drugs for clinical indication - hypersensitivity to acetylsalicylic acid or to any of the excipients - hypersensitivity to non-steroidal anti-inflammatory drugs (nsaids) - severe hepatic insufficiency (child-pugh class c). - severe heart failure (nyha class 3-4) - platelet count less than 150000 / mmc - haemostasis alteration (inr> 1.5, aptt> 1.5) - plasma fibrinogen <100 mg / dl - blood pressure >160/100 mmhg - concomitant treatment with serotonin reuptake inhibitors - participation in another pharmacological clinical trial